Nationaler Pandemieplan

Objectives

Germany’s National Pandemic Plan provides a national framework for preparedness for and response to influenza pandemics. Part I describes response structures and measures for planning and management, while Part II provides the scientific foundations, standards and evidence for decision-making.[1][2][3]Its overarching aims are to reduce morbidity and mortality, ensure care for ill people, sustain essential public services and provide reliable, timely information to decision-makers, professionals, the public and the media.[4]

• Establish flexible, risk-based preparedness and response that is adapted to national, regional and local epidemiological conditions rather than determined solely by World Health Organization global pandemic phases.[4][5][6]
• Assess pandemic risk continuously through epidemic potential, the epidemiological severity profile of illness and pressure on health-system resources.[7][8][9]
• Detect emerging, zoonotic and pandemic influenza viruses early through human and animal surveillance, laboratory diagnosis, virological characterisation and statutory notification.[10][11][12]
• Limit transmission and consequences through infection prevention, contact-reduction measures, diagnostics, medical care, vaccination, antiviral medicines, continuity planning and risk communication.[13][14][15]
• Protect people at increased risk of severe disease, healthcare personnel and essential services, while preserving ambulatory, hospital, emergency and residential-care capacity.[14][16][17]
• Evaluate the pandemic course, measures and response structures after the event, and use lessons learned to optimise subsequent preparedness.[18][14]

The scientific component supports proportionate decisions under uncertainty, drawing on lessons from the 2009 H1N1 pandemic, international evaluations and evidence reviews.[3][19][20]It covers epidemiology, virology, diagnostics, surveillance, risk assessment, non-pharmaceutical interventions, vaccines, pandemic-relevant medicines, clinical management and communication, but does not itself provide operational recommendations, which are addressed in Part I.[21][3][22]

Surveillance is intended to provide continuous, representative information across the severity spectrum, from community illness and primary care to hospitalisation, intensive care and mortality, and to enable comparison with historical seasonal data.[23][24][9]The plan envisages combining syndromic, virological, statutory laboratory, hospital, mortality and population-based surveillance with targeted studies and, where appropriate, modelling to inform decision-making.[25][26][27]

Implementation

Implementation follows Germany’s federal structure: federal, Länder and municipal authorities and institutions undertake coordinated planning, with Länder pandemic plans forming the basis for municipal and local public-health implementation.[1][4]Preparedness also depends on organisations beyond the health system, including healthcare providers, care services, emergency medical services, employers, critical infrastructure operators and the public.[4][28][29]

• Coordinate federal and Länder planning through the Federal-Länder Working Group on Pandemic Planning, the Conference of Health Ministers and specialist working groups on infection protection, surveillance, hospitals, medicines, pharmacies and emergency services.[30][31][32]
• Lead federal crisis management through the Federal Ministry of Health, supported by its crisis management team, and establish joint arrangements with the Federal Ministry of the Interior for nationally significant incidents affecting health and internal security.[33][31]
• Use the Robert Koch Institute to collect and analyse epidemiological data, advise Länder authorities, coordinate technical investigations and measures, facilitate international information flows and lead scientific risk assessment.[33][34]
• Draw on specialist advice from the Influenza Expert Advisory Board, the Paul-Ehrlich-Institut for vaccine matters and adverse reactions, the Federal Institute for Drugs and Medical Devices for medicine and device benefit-risk assessment, and the Federal Centre for Health Education for nationwide public communication.[33][31]
• Maintain international coordination through the International Health Regulations focal point, the World Health Organization, the European Centre for Disease Prevention and Control, European early-warning systems and the Health Security Committee.[35][36]

Operational preparedness includes defining responsibilities and cost-bearing arrangements; reserving, procuring and storing medicines, vaccines and protective materials; establishing diagnostics, reporting and communication channels; planning hospitals and critical infrastructure; and exercising crisis management.[37][31][38]The plan identifies federal reserves of oseltamivir and Relenza to supplement Länder stocks, including 7.5 million oseltamivir treatment units and 1.5 million Relenza treatment units.[39]

Response measures are escalated or de-escalated according to changing assessments. Early action can focus on case identification, contact tracing, containment and targeted diagnostics; sustained transmission shifts emphasis towards protecting vulnerable groups, maintaining healthcare capacity, reducing severe outcomes and managing consequences.[40][41][42]Public-health authorities may investigate cases, interrupt transmission chains, trace contacts and apply legally authorised isolation, activity restrictions, closures of community facilities and supplementary vaccination measures.[41][43]

Healthcare delivery arrangements include segregated influenza pathways, triage, cohort isolation, expanded treatment and ventilation capacity, postponement of elective procedures where necessary, staff protection and rapid procurement or stockpiling of medicines and personal protective equipment.[38][17][44]Ambulatory care is coordinated through statutory health insurance physician associations and relevant community clinicians, while Länder plans may designate specialist practices or broader community-doctor arrangements.[38]

Vaccination planning combines risk-benefit assessment, expert recommendations, forward contracts, potential European Union joint procurement, Länder-led storage and distribution, and delivery through public health services, community doctors and occupational physicians.[45][46][47]Initial vaccine supply should prioritise groups most likely to benefit, including healthcare personnel, people at increased health risk and pregnant women, with recommendations updated as evidence, vaccine characteristics and availability change.[48][49]Vaccine safety and coverage monitoring should record suspected adverse reactions promptly and assess uptake by age and target group.[50][51]

Communication is a core delivery mechanism before, during and after a pandemic. Authorities should prepare plans and messages in advance, coordinate information across municipal, Länder and federal levels, communicate transparently about evidence and uncertainty, use mass media and digital channels, and tailor materials to different population groups and languages.[52][53][54]The plan does not specify a consolidated national performance-indicator set, quantified budget or formal accountability framework, although it provides continuous surveillance, statutory reporting, exercises, review and post-pandemic evaluation mechanisms.[18][55][22]

Monitoring & Evaluation

The plan establishes a comprehensive surveillance, risk-assessment and learning architecture for influenza pandemics, combining statutory notification, sentinel and population surveillance, laboratory confirmation, hospital and mortality monitoring, targeted studies, and continuous communication of findings. It uses this evidence to adapt measures to national and regional conditions rather than relying solely on global pandemic phases.[4][55][34]

• Maintain continuous collection, analysis, assessment and timely reporting of health data, using representative sources, severity-specific information, denominators and historical seasonal baselines where possible.[56][23][9]
• Monitor human and animal influenza surveillance, targeted virus subtypes, acute respiratory infections, influenza-like illness, laboratory-confirmed infection, hospitalisations, intensive-care demand, mortality and excess mortality.[37][57][10][25][58]
• Require direct detection of influenza viruses to be notified through health authorities to the Robert Koch Institute, generally by the next working day, using applicable case definitions.[59]
• Use SurvNet@RKI to manage, transmit and analyse notifications and SurvStat@RKI to provide user-defined tables and graphs on notifiable diseases and pathogen detections.[60][57]
• Operate complementary systems including the Arbeitsgemeinschaft Influenza sentinel, GrippeWeb population reporting, practice-based electronic recording, virological surveillance, hospital surveillance and civil-registration mortality surveillance.[57][61][62][10]
• Strengthen nationwide hospital surveillance, as the previous voluntary pandemic system had limited participation and did not provide seasonal baseline data.[62]
• Transmit syndromic and virological sentinel findings weekly through European and global channels, with the Robert Koch Institute reporting through the European Influenza Surveillance Network, European Centre for Disease Prevention and Control and World Health Organization.[63]
• Notify the World Health Organization without delay of relevant events during a public health emergency of international concern, including novel-subtype influenza, imported cross-border risks, response measures and travel or trade measures.[35][59]
• Apply continuous, differentiated risk assessment across epidemic potential, clinical severity and health-system burden, using virological, epidemiological and clinical information and reassessing conclusions as evidence improves.[7][34][8]
• Use indicators including case growth, reproduction numbers, household and clinical attack rates, cross-reactive immunity, hospitalisation, intensive-care use, ventilation, mortality, staff absence, laboratory workload and public-health capacity.[64][65][66]
• Conduct preparedness exercises and reviews, including cross-sectoral Federation-Länder exercises every two years, and evaluate response structures and measures after a pandemic to improve future planning.[31][18]
• Monitor vaccine safety through pharmacovigilance reporting to the Paul-Ehrlich-Institut, record adverse reactions promptly, and measure vaccination coverage by age and target group; a nationally uniform timely coverage-recording system was not yet available.[50][67][68]
• Monitor antiviral stock quality through regular stability studies and monitor antiviral resistance through National Reference Centre for Influenza surveillance and representative testing of confirmed viruses.[69][70]
• Assess communication through public understanding, acceptance and adherence, pre-test messages for at-risk and difficult-to-reach groups, monitor public questions and social-media misinformation, and review crisis communication after the event.[71][72][73]

Formal consolidated performance targets, a single national indicator set, independent evaluation procedures and a comprehensive accountability framework are not specified beyond statutory reporting, institutional responsibilities, surveillance arrangements, exercises and post-event review.[32][23][34]

Costing & Financing

The plan identifies substantial preparedness, procurement, service-capacity and continuity requirements, but does not provide an overall pandemic budget, monetary allocations, funding-gap estimate or economic assumptions. Financing responsibilities are described only for selected diagnostics, vaccines and antivirals.[37][74][75]

• Arrange responsibility for preparedness costs and reserve, procure and store medicines, vaccines and materials.[37]
• Use antiviral stockpiles, contractual vaccine-production capacity, forward contracts with manufacturers and possible European Union joint procurement to support availability of vaccines and medicines.[30][45][46][39]
• Reimburse medically indicated diagnostic services linked to the applicable case definition through statutory health insurance, including services supporting post-exposure prophylaxis or patient treatment.[76]
• Fund public-health investigations undertaken solely for epidemiological knowledge or initiation of infection-control measures from public funds.[76]
• Expect statutory health insurance to bear antiviral treatment costs, while leaving reimbursement arrangements for federal and Länder antiviral reserves uncommunicated and requiring advance clarification of federal cost responsibility for prophylactic use.[74]
• Organise vaccine financing under federal legal provisions, with a Federal Ministry of Health ordinance expected to shape subsequent Länder-level agreements; no quantified vaccine budget is specified.[47]
• Recognise resource risks during prolonged crises, including exhaustion of personnel and materials, and prepare additional treatment capacity, vaccine logistics, protective equipment, medicines, oxygen, ventilation and staffing.[77][16][17]
• Provide institutions with responsibility for maintaining protective clothing and other required supplies, supported where necessary by stockpiling or rapid procurement arrangements.[78][79]
• Recognise qualitative cost differences across surveillance approaches: online population surveys are comparatively low-cost, primary-care sentinel surveillance has medium costs, hospital and maximum-care surveillance have high costs, and mortality surveillance has medium costs when information-technology systems and algorithms already exist.[25][80]
• Consider economic and operational consequences of restrictive measures, including parental work absence from school closures, business-continuity risks, substantial staffing demands for border screening, and potentially massive costs of border closure.[81][82][83]
• Use intensified hand hygiene as a low-cost, rapidly implementable measure with few adverse effects, while recognising that no monetary estimate is supplied.[84][85]

Resource efficiency is an explicit consideration for adjuvanted vaccines, which can reduce antigen required per dose and increase output from available manufacturing capacity; single-dose vaccine presentation requires greater production, storage, transport and packaging capacity than multi-dose containers.[86][87][46]

Except for the stated postage charge for a printed copy, the source supplies no monetary values for preparedness actions, procurement, service capacity, surveillance, communications or response interventions.[88]